Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by CenterBook Partners LP

CenterBook Partners LP decreased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 64.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,509 shares of the biopharmaceutical company's stock after selling 197,090 shares during the period. CenterBook Partners LP owned about 0.19% of Agios Pharmaceuticals worth $3,179,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth about $39,000. CWM LLC raised its position in shares of Agios Pharmaceuticals by 150.2% during the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 996 shares in the last quarter. Sterling Capital Management LLC raised its position in shares of Agios Pharmaceuticals by 818.0% during the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after acquiring an additional 1,587 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of Agios Pharmaceuticals by 16.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock worth $105,000 after acquiring an additional 499 shares in the last quarter. Finally, AlphaQuest LLC raised its position in shares of Agios Pharmaceuticals by 106.2% during the 4th quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock worth $149,000 after acquiring an additional 2,338 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on AGIO. Scotiabank cut their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research report on Friday, May 2nd. Wall Street Zen lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Agios Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $58.60.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,770 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $92,905.80. Following the sale, the insider directly owned 26,122 shares in the company, valued at $876,131.88. The trade was a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Sarah Gheuens sold 11,914 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $37.99, for a total value of $452,612.86. Following the transaction, the insider directly owned 61,271 shares of the company's stock, valued at approximately $2,327,685.29. This represents a 16.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,363 shares of company stock valued at $1,619,654. 4.30% of the stock is owned by company insiders.

Agios Pharmaceuticals Stock Up 0.9%

AGIO traded up $0.36 during trading on Thursday, hitting $40.35. 812,972 shares of the stock were exchanged, compared to its average volume of 657,998. The firm has a market capitalization of $2.34 billion, a P/E ratio of 3.59 and a beta of 0.73. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58. The stock has a fifty day moving average price of $33.35 and a two-hundred day moving average price of $32.16.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, beating the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.75% and a net margin of 1,798.26%. The company had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.86 million. Analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.